Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease
Kazushi Numata(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Makoto Chuma(Yokohama City University Medical Center), Masahiro Okada, Akito Nozaki(Yokohama City University Medical Center), Hiromi Nihonmatsu(Yokohama City University Medical Center), Masaaki Kondo(Yokohama City University Medical Center), Hiroyuki Fukuda(Yokohama City University Medical Center), Takashi Oshima(Kanagawa Prefectural Hospital Organization), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Masayuki Nakano(Nihon University), Yoshiaki Inayama(Yokohama City University Medical Center), Takamichi Murakami(Kobe University Hospital), Shigeo Takebayashi(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital)
Cited by 36
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573